These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 2892924)
1. Effects of three new anthracyclines and doxorubicin on the rat isolated heart. Chen ZM; Colombo T; Conforti L; Grazia Donelli M; Fiedorowicz RJ; Marchi S; Paolini A; Riva E; Zuanetti G; Latini R J Pharm Pharmacol; 1987 Nov; 39(11):947-50. PubMed ID: 2892924 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186 [TBL] [Abstract][Full Text] [Related]
3. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759 [TBL] [Abstract][Full Text] [Related]
4. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Platel D; Pouna P; Bonoron-Adèle S; Robert J Anticancer Drugs; 1999 Aug; 10(7):671-6. PubMed ID: 10507317 [TBL] [Abstract][Full Text] [Related]
5. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines. Cini-Neri G; Neri B Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425 [TBL] [Abstract][Full Text] [Related]
6. Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart. Platel D; Bonoron-Adèle S; Robert J Pharmacol Toxicol; 2001 May; 88(5):250-4. PubMed ID: 11393585 [TBL] [Abstract][Full Text] [Related]
7. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Wadler S; Fuks JZ; Wiernik PH J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics of new anthracyclines]. Robert J Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579 [TBL] [Abstract][Full Text] [Related]
9. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Nazeyrollas P; Prévost A; Baccard N; Manot L; Devillier P; Millart H Cancer Chemother Pharmacol; 1999; 43(3):227-32. PubMed ID: 9923553 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity. Swift L; McHowat J; Sarvazyan N Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926 [TBL] [Abstract][Full Text] [Related]
11. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Robert J Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747 [TBL] [Abstract][Full Text] [Related]
12. Integration of cardiac energetics, function and histology from isolated rat hearts perfused with doxorubicin and doxorubicin-ol; a model for use in drug safety evaluations. Henderson KA; Borders RB; Ross JB; Abdulalil A; Gibbs S; Skowronek AJ; Knostman K; Bailey J; Smith J; Vinci T; Wood B; Knopp MV; Roche BM J Pharmacol Toxicol Methods; 2018; 94(Pt 2):54-63. PubMed ID: 30195582 [TBL] [Abstract][Full Text] [Related]
14. Acute anthracycline cardiotoxicity. Comparative morphologic study of three analogues. Taylor AL; Applefeld MM; Wiernik PH; Grochow LB; Mader LC; Bulkley BH Cancer; 1984 Apr; 53(8):1660-6. PubMed ID: 6582997 [TBL] [Abstract][Full Text] [Related]
15. The role of biotransformation in anthracycline-induced cardiotoxicity in mice. de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139 [TBL] [Abstract][Full Text] [Related]
16. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. Dorr RT; Bozak KA; Shipp NG; Hendrix M; Alberts DS; Ahmann F Cancer Res; 1988 Sep; 48(18):5222-7. PubMed ID: 3409247 [TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. Platel D; Pouna P; Bonoron-Adèle S; Robert J Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671 [TBL] [Abstract][Full Text] [Related]
18. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Della Torre P; Podestà A; Imondi AR; Moneta D; Sammartini U; Arrigoni C; Terron A; Brughera M Cancer Chemother Pharmacol; 2001 Apr; 47(4):355-60. PubMed ID: 11345653 [TBL] [Abstract][Full Text] [Related]
19. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734 [TBL] [Abstract][Full Text] [Related]
20. The rat model in the comparative evaluation of anthracyclines cardiotoxicity. Lanza E; Rozza A; Favalli L; Monti E; Poggi P; Villani F Tumori; 1989 Dec; 75(6):533-6. PubMed ID: 2617699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]